(Q36742056)

16 August 2017

1 reference

title

Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma (English)

1 reference

16 August 2017

0 references

2

Bruce G Robinson

1 reference

16 August 2017

Marinella Messina

1

1 reference

16 August 2017

language of work or name

1 reference

1 March 2007

1 reference

Nature Clinical Practice Endocrinology and Metabolism

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

290-301

1 reference

Transductional targeting of adenoviral cancer gene therapy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

An intron enhancer containing a 5' splice site sequence in the human calcitonin/calcitonin gene-related peptide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Surgical treatment of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

C-cell cancer--prevention and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

1 reference

7 January 2021

Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Transcriptional Regulatory Sequences of Carcinoembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

The RET proto-oncogene: a potential target for molecular cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Antisense therapy in malignant diseases: status quo and quo vadis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Calcitonin secretion, C cell differentiation and proliferation during the spontaneous development of murine medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

A mechanistic analysis of nitric oxide-induced cellular toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Immunomodulation of cancer: potential use of selectively replicating agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

The toxicology of interleukin-12: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Adenoviral vectors for gene transfer and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Inducing autoimmune disease to treat cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Adenoviral strategies for the gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Gene-based vaccines and immunotherapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Tissue-specific promoters for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Replication-selective oncolytic viruses in the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

The Ret proto-oncogene in the WAG/Rij rat strain: an animal model for inherited C-cell carcinoma?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0420

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0420

1 reference

release_ughv2krtmnhp3ktc6i5oc43nbm

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ughv2krtmnhp3ktc6i5oc43nbm

24 November 2022

mapped directly with Wikidata item

1 reference